VectivBio Holding AG (VECT) Fundamental Analysis & Valuation

NASDAQ:VECT • CH1109007893

Current stock price

16.85 USD
0 (0%)
Last:

This VECT fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. VECT Profitability Analysis

1.1 Basic Checks

  • In the past year VECT has reported negative net income.
  • VECT had a negative operating cash flow in the past year.
VECT Yearly Net Income VS EBIT VS OCF VS FCFVECT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 -20M -40M -60M -80M

1.2 Ratios

  • The profitability ratios for VECT are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VECT Yearly ROA, ROE, ROICVECT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 -50 -100 -150 -200 -250

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for VECT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VECT Yearly Profit, Operating, Gross MarginsVECT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. VECT Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, VECT has more shares outstanding
  • Compared to 1 year ago, VECT has a worse debt to assets ratio.
VECT Yearly Shares OutstandingVECT Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 20M 40M 60M
VECT Yearly Total Debt VS Total AssetsVECT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 50M 100M 150M 200M 250M

2.2 Solvency

  • VECT has an Altman-Z score of 17.24. This indicates that VECT is financially healthy and has little risk of bankruptcy at the moment.
  • VECT's Altman-Z score of 17.24 is amongst the best of the industry. VECT outperforms 93.55% of its industry peers.
  • A Debt/Equity ratio of 0.05 indicates that VECT is not too dependend on debt financing.
  • VECT has a Debt to Equity ratio (0.05) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z 17.24
ROIC/WACCN/A
WACCN/A
VECT Yearly LT Debt VS Equity VS FCFVECT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 0 50M -50M 100M 150M 200M

2.3 Liquidity

  • A Current Ratio of 9.14 indicates that VECT has no problem at all paying its short term obligations.
  • The Current ratio of VECT (9.14) is better than 71.13% of its industry peers.
  • A Quick Ratio of 9.14 indicates that VECT has no problem at all paying its short term obligations.
  • With a decent Quick ratio value of 9.14, VECT is doing good in the industry, outperforming 71.29% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.14
Quick Ratio 9.14
VECT Yearly Current Assets VS Current LiabilitesVECT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. VECT Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 22.00% over the past year.
EPS 1Y (TTM)22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.83%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 19.85% on average over the next years. This is quite good.
  • Based on estimates for the next years, VECT will show a very strong growth in Revenue. The Revenue will grow by 81.29% on average per year.
EPS Next Y8.67%
EPS Next 2Y1.86%
EPS Next 3Y1.79%
EPS Next 5Y19.85%
Revenue Next Year-96.99%
Revenue Next 2Y-36.77%
Revenue Next 3Y44.85%
Revenue Next 5Y81.29%

3.3 Evolution

VECT Yearly Revenue VS EstimatesVECT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
VECT Yearly EPS VS EstimatesVECT Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2

More info and screens

Find the best growth stocksShow best growing peers

0

4. VECT Valuation Analysis

4.1 Price/Earnings Ratio

  • VECT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VECT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VECT Price Earnings VS Forward Price EarningsVECT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VECT Per share dataVECT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.86%
EPS Next 3Y1.79%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. VECT Dividend Analysis

5.1 Amount

  • VECT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

VECT Fundamentals: All Metrics, Ratios and Statistics

VectivBio Holding AG

NASDAQ:VECT (7/7/2023, 8:07:59 PM)

16.85

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-19
Earnings (Next)N/A
Inst Owners0.81%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap1.06B
Revenue(TTM)N/A
Net Income(TTM)-93.73M
Analysts47.5
Price Target18.36 (8.96%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)0
Avg Revenue beat(4)-100%
Min Revenue beat(4)-100%
Max Revenue beat(4)-100%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.93%
PT rev (3m)-20%
EPS NQ rev (1m)0%
EPS NQ rev (3m)4.44%
EPS NY rev (1m)0%
EPS NY rev (3m)14.96%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.95
P/tB 5.65
EV/EBITDA N/A
EPS(TTM)-1.87
EYN/A
EPS(NY)-1.81
Fwd EYN/A
FCF(TTM)-0.9
FCFYN/A
OCF(TTM)-0.9
OCFYN/A
SpS0
BVpS3.4
TBVpS2.98
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 30.96%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.14
Quick Ratio 9.14
Altman-Z 17.24
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)27.7%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.83%
EPS Next Y8.67%
EPS Next 2Y1.86%
EPS Next 3Y1.79%
EPS Next 5Y19.85%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-96.99%
Revenue Next 2Y-36.77%
Revenue Next 3Y44.85%
Revenue Next 5Y81.29%
EBIT growth 1Y7.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-47.69%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y21.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y22.01%
OCF growth 3YN/A
OCF growth 5YN/A

VectivBio Holding AG / VECT Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for VectivBio Holding AG?

ChartMill assigns a fundamental rating of 2 / 10 to VECT.


What is the valuation status for VECT stock?

ChartMill assigns a valuation rating of 0 / 10 to VectivBio Holding AG (VECT). This can be considered as Overvalued.


How profitable is VectivBio Holding AG (VECT) stock?

VectivBio Holding AG (VECT) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for VECT stock?

The Earnings per Share (EPS) of VectivBio Holding AG (VECT) is expected to grow by 8.67% in the next year.